SMi Group is proud to announce the return of Drug Discovery in 2018. The successful conference will return for its 2nd year on the 21st and 22nd March.

The pharmaceutical industry is constantly battling the same issue when trying to discover drugs; the process is timely, expensive and usually unsuccessful. Pharma companies are trying to speed up the procedure to make it more accurate and minimise drug leads which are likely to fail further on in the drug development process. Consequently, the event will focus on key developments in this very industry.

SMi’s 2^nd annual Drug Discovery conference provides an unprecedented opportunity to gain insight into the use of Artificial Intelligence in silico drug discovery, CRISPR and PROTAC’s, as well as discussing advancements in medicinal chemistry, translational medicine and 3D structure based-discovery.

With huge interest from leaders in the field, we have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Drug Discovery yet. This year’s event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations from our confirmed Industry-leading speakers:

– Chairman – Darren Green, Director of Computational Chemistry and Informatics, GlaxoSmithKline plc
– Chairman – Guido Hanauer, CEO, GHPC GmbH
– Steve Rees, Vice-President, Screening Sciences and Sample Management at AstraZeneca, Astra Zeneca Plc
– Claus Bendtsen, Executive Director/Sr Leader Data Science, AstraZeneca
– Ralph Minter, Director, Fellow, Antibody Discovery and Protein Engineering, MedImmune
– Stevan Djuric, Vice President, AbbVie
– John Harling, Director of Chemistry for the Protein Degradation DPU, GlaxoSmithKline plc
– Ursula Egner, Director Process Simulation and Design Collaboration, Bayer HealthCare

Early bird discounts!

• Register by the 30^th November to save £400
• 15^th December to save £200
• 31^st January to save £100